ArticleBMJ open2022
Epicardial injection of allogeneic human-induced-pluripotent stem cell-derived cardiomyocytes in patients with advanced heart failure: protocol for a phase I/IIa dose-escalation clinical trial.
Article in BMJ open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03763136 (Epicardial Injection of Allogeneic Human Pluripotent Stem Cell-derived Cardiomyocytes to Treat Severe Chronic Heart Failure), which is not on this map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Epicardial Injection of Allogeneic Human Pluripotent Stem Cell-derived Cardiomyocytes to Treat Severe Chronic Heart Failure
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Induced pluripotent stem cell therapies in heart failure treatment: a meta-analysis and systematic review.Regenerative medicinePooled it
- Induced pluripotent stem cells from discovery to translation.Nature medicine · 2026Review
- Biologics for cardiovascular diseases: from bench to bedside.Signal transduction and targeted therapy · 2026Review
- Accelerated Intrinsic Beating Rate in Heterogeneously Coupled Human Pluripotent Stem Cell-Derived Cardiomyocytes Can Underlie Focal Ventricular Tachycardia in Regenerative Therapy.Journal of precision medicine (Amsterdam, Netherlands) · 2026Article
- A Review of the Therapeutic Efficacy and Safety of Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes in Preclinical Models of Subacute and Chronic Myocardial Infarction.Journal of cardiovascular development and disease · 2026Review
- A comprehensive review of clinical trials and Progress in stem cell therapies for advanced heart failure.Regenerative therapy · 2025Review
- Review
- Pluripotent stem cell-derived cardiomyocyte transplantation: marching from bench to bedside.Science China. Life sciences · 2025Review
- Engineering a controlled cardiac multilineage co-differentiation process using statistical design of experiments.Stem cell research & therapy · 2025Article
- Article
- Interpenetrating network hydrogel-loaded embryonic stem cell-derived endocardial cells improves cardiac function after myocardial infarction.Journal of translational medicine · 2025Article
- Trials and tribulations of cell therapy for heart failure: an update on ongoing trials.Nature reviews. Cardiology · 2025Review
- Inhibition of polymorphonuclear cells averts cytotoxicity against hypoimmune cells in xenotransplantation.Nature communications · 2025Article
- Transcriptome and epigenome dynamics of the clonal heterogeneity of human induced pluripotent stem cells for cardiac differentiation.Cellular and molecular life sciences : CMLS · 2024Article
- Current Status of Cardiac Regenerative Therapy Using Induced Pluripotent Stem Cells.International journal of molecular sciences · 2024Review
- Role of Cx43 in iPSC-CM Damage Induced by Microwave Radiation.International journal of molecular sciences · 2023Article
- Cells and Materials for Cardiac Repair and Regeneration.Journal of clinical medicine · 2023Review
- Unlocking the Pragmatic Potential of Regenerative Therapies in Heart Failure with Next-Generation Treatments.Biomedicines · 2023Review
- Advances in 3D Organoid Models for Stem Cell-Based Cardiac Regeneration.International journal of molecular sciences · 2023Review
- Cell-Based and Selected Cell-Free Therapies for Myocardial Infarction: How Do They Compare to the Current Treatment Options?International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHeart failure (HF) is a growing global public health burden. However, due to the very limited regenerative capacity of mature cardiomyocytes in the adult mammalian heart, conventional treatments can only improve the symptoms of HF but fail to restore cardiac function. Heart transplantation is limited by a severe shortage of donors. Cell-based transplantation for the treatment of HF has become a promising strategy. Human-induced-pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) have been tested in animal models to assess safety and efficacy. This study aims at evaluating the safety and efficacy of epicardial injection of hiPSC-CMs in patients with advanced HF during coronary artery bypass grafting (CABG) surgery.
methodsThis study is a dose-escalation, placebo-controlled, single-centre phase I/IIa clinical trial. Dose escalation will be guided by a modified 3+3 design for three doses (1×10 ETHICS AND DISSEMINATION: The study protocol has been approved by the Institutional Ethical Committee of Nanjing Drum Tower Hospital (No. SC202000102) and approved by National Health Commission of the PRC (MR-32-21-014649). Findings will be disseminated to the academic community through peer-reviewed publications and presentation at national and international meetings. TRIAL REGISTRATION NUMBER: NCT03763136.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.